扶正抑瘤汤对肝癌细胞侵袭转移能力影响的研究

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (687 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Fuzheng Yiliu Decoction on invasion and metastasis of hepatocellular carcinoma cells (HCC). Methods Hepatocellular carcinoma cells were treated by Fuzheng Yiliu Decoction. MTT assay was used to detect the proliferation of hepatocellular carcinoma cells. The migration ability of HCC cells was detected by scratch test, while the invasion ability of HCC cells was detected by Transwell assay. Results MTT results showed that in HCC lines HepG2, MHC97-H, the proliferation ability of 400 mg/mL Fuzheng Yiliu Decoction group was significantly lower than the control group (P < 0.05). Scratch test demonstrated that in liver cancer cell MHC97-H, the migration rate of liver cancer cells in Fuzheng Yiliu Decoction 400 mg/mL group was significantly lower than that in the control group (P < 0.05). Transwell experiment proved that in liver cancer cell MHC97-H, the number of invading hepatoma cells in the 400 mg/mL Fuzheng Yiliu Decoction group was significantly lower than that in the control group (P < 0.05). Conclusion Fuzheng Yiliu Decoction can inhibit the proliferation, invasion and metastasis of HCC.

Key words： Hepatocellular carcinoma Fuzheng Yiliu Decoction Proliferation Invasion and metastasis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PENG Jianxin HE Junming CAI Bingqing CHEN Guihao LIU Ming

Cite this article:

PENG Jianxin HE Junming CAI Bingqing CHEN Guihao LIU Ming. Study on the effect of Fuzheng Yiliu Decoction on invasion and metastasis of hepatocellular carcinoma cells[J]. 中国医药导报, 2018, 15(10): 25-28.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I10/25

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2016.[J]. CA Cancer J Clin，2016，66（1）：7-30.
[2] Ramachandran J. Surveillance for hepatocellular carcinoma [J]. J Clin Exp Hepatol，2014，4（Suppl 3）：S50-S56.
[3] Facciorusso A，Serviddio G，Muscatiello N. Local ablative treatments for hepatocellular carcinoma：，An updated review [J]. World J Gastrointest Pharmacol Ther，2016，7（4）：477-489.
[4] 陈宝定，魏金文，薛玉，等.超声引导射频消融治疗小肝癌27例的疗效分析[J].中国医药导报，2012，9（34）：62-63，70.
[5] Wei Q，Xu X，Wang C. Efficacy and Safety of a Steroid-Free Immunosuppressive Regimen after Liver Transplantation for Hepatocellular Carcinoma [J]. Gut Liver，2016，10（4）：604-610.
[6] 刘波，杨扬.肝细胞肝癌肿瘤新生血管与抗癌治疗[J].中华肝脏外科手术学电子杂志，2013，2（4）：54-56.
[7] Meng Q，He X，Xie G. MEK inhibitor enhances sensitivity to chemotherapeutic drugs in multidrug resistant hepatocellular carcinoma cells [J]. Oncol Lett，2017，14（3）：3089-3095.
[8] Limoge M，Safina A，Beattie A. Tumor-fibroblast interactions stimulate tumor vascularization by enhancing cytokine-driven production of MMP9 by tumor cells [J]. Oncotarget，2017，8（22）：35592-35608.
[9] 欧杰，陈闯，诸佳瑜，等.175例原发性肝癌中医证型与Child-Pugh分级相关性的研究[J].四川中医，2017，35（1）：54-57.
[10] 汪猛，秦凯健，杨梦琪，等.原发性肝癌的中医药诊治研究进展[J].中医药导报，2015，21（3）：49-52.
[11] 何秀兰，周而复，袁尚华.王沛教授治肝癌临床经验总结[J].中国中医基础医学杂志，2004，10（3）：70-71.
[12] 谢晶日，赵刚，梁国英.原发性肝癌的中医药现代研究进展[J].中国医药导报，2008，5（7）：17-18.
[13] 高玉琼，韩聪，朱国福.钱伯文教授运用莪术治疗恶性肿瘤的经验[J].中医药导报，2017，23（7）：70-72.
[14] 顾军花，刘嘉湘.刘嘉湘教授“扶正治癌”理论核心及运用方法[J].中国中西医结合杂志，2017，37（4）：495-499.
[15] 汪猛，秦凯健，杨梦琪，等.原发性肝癌的中医药诊治研究进展[J].中医药导报，2015，21（3）：49-52.
[16] 赵红佳，杜建，陈曦，等.扶正抑瘤方协同微波消融治疗肝癌的临床研究[J].中国中西医结合志，2012，1（1）：32-34.
[17] 蔡翊，王群伟.黄芪总皂苷抗肝癌活性研究[J].中国现代医学杂志，2011，21（34）：4258-4260.
[18] 徐榕，许津，姚晨.茯苓中集落刺激因子诱生剂的分离与鉴定[J].药学服务与研究，2005，5（4）：378，384.
[19] 郑君婷，杨竣联.杜建教授扶正抑瘤汤在消化道肿瘤治疗中地位[J].福建中医药大学学报，2009，2（2）：13-14.
[20] Hsu HY，Yu MC，Lee CW. RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma [J]. BMC Cancer，2017， 17（1）：742.